Centaurus Financial Inc. Takes Position in Medpace Holdings, Inc. $MEDP

Key Points

• Centaurus Financial purchased 1,814 Medpace shares worth approximately $961,000 in the second quarter, while institutional investors collectively own 77.98% of the stock.
• Medpace insiders have sold 133,821 shares worth roughly $81.7 million over the past three months, including substantial sales by a director and the CFO.
• Medpace reported better-than-expected quarterly results, with EPS of $4.25 and revenue of $707.33 million, up 17.2% year over year. Analysts maintain a consensus “Hold” rating with an average price target of $584.18.

Centaurus Financial Inc. purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,814 shares of the company's stock, valued at approximately $961,000.

A number of other institutional investors also recently bought and sold shares of MEDP. NewEdge Advisors LLC raised its stake in shares of Medpace by 22.1% in the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company's stock valued at $319,000 after acquiring an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Medpace by 3.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company's stock worth $24,929,000 after purchasing an additional 3,010 shares during the period. Geneos Wealth Management Inc. boosted its stake in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares during the period. Sivia Capital Partners LLC bought a new position in Medpace during the 2nd quarter valued at about $296,000. Finally, M&T Bank Corp grew its holdings in Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company's stock valued at $295,000 after purchasing an additional 31 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Insider Transactions at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 7,283 shares of the company's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the completion of the sale, the director owned 3,798 shares in the company, valued at $2,302,157.70. This represents a 65.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kevin M. Brady sold 3,400 shares of the stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $625.24, for a total value of $2,125,816.00. Following the sale, the chief financial officer directly owned 12,830 shares in the company, valued at $8,021,829.20. This trade represents a 20.95% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 133,821 shares of company stock worth $81,748,135. Insiders own 20.50% of the company's stock.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Weiss Ratings raised shares of Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 12th. Robert W. Baird upped their target price on Medpace from $547.00 to $624.00 and gave the company a "neutral" rating in a research note on Friday, July 24th. BMO Capital Markets increased their price target on Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a report on Friday, July 24th. Mizuho raised their price target on Medpace from $586.00 to $665.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a $535.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, Medpace presently has an average rating of "Hold" and an average price target of $584.18.

Medpace Price Performance

NASDAQ:MEDP opened at $600.65 on Friday. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The company has a 50-day moving average of $565.33 and a 200 day moving average of $494.55. The firm has a market cap of $16.76 billion, a PE ratio of 35.21, a price-to-earnings-growth ratio of 2.73 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analysts' expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm's quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source